U.S. Defense Health Agency selects Amwell® and Leidos to power the Digital First initiative for the U.S. Military Health System

U.S. Defense Health Agency selects Amwell® and Leidos to power the Digital First initiative for the U.S. Military Health System

The Amwell ConvergeTM platform will enable DHA healthcare teams to deliver connected and seamless in-person, virtual, and automated care delivery for the Military Health System

BOSTON — Oct. 19 2023, — Amwell® (NYSE: AMWL), a leader in hybrid healthcare enablement, together with Leidos (NYSE: LDOS), a FORTUNE® 500 science and technology leader, was recently awarded a next-generation contract to provide a hybrid care technology platform designed to power the “Digital First” transformation of the Military Health System (MHS).

Under this task order, the Leidos Partnership for Defense Health (LPDH) will deliver Amwell ConvergeTM, a comprehensive hybrid care enablement platform designed to power the full continuum of care using digital, virtual and automated modalities, and replace the Military Health System (MHS) Video Connect solution. It will start at five initial sites followed by a phased enterprise roll-out. Also included in the contract are a broad spectrum of Amwell automated care programs that have a proven track record of helping deliver better health outcomes, including multiple behavioral health and integrated core telehealth solutions. If all options are exercised, the task order has a 22-month period of performance with a total value of up to $180 million to the LPDH.

“Through our world class platform Converge, Amwell is already enabling hybrid care across the commercial marketplace. With this agreement, we are pleased to offer our unique capabilities and help improve access to quality care for the MHS community of users. We are grateful for their service, and honored to have been chosen to join Leidos in supporting the Department of Defense as it seeks to adopt and extend the benefits of hybrid care to the Military Health System,” said Ido Schoenberg, M.D., chairman and CEO of Amwell.

The DHA’s Digital First initiative brings new capabilities and enablement to MHS GENESIS, an advanced electronic health record (EHR) and healthcare system solution that supports military and Veteran healthcare initiatives. The Converge platform has deep integration assets and a simple yet powerful user experience that enables efficient and quality hybrid care delivery. The platform is already embedded into existing clinical workflows that care teams rely on, including those within the core EHR that powers MHS GENESIS. Together, Amwell and LPDH will enable the DHA to leverage the benefits of hybrid care, improve access to primary and behavioral health care, and ultimately improve outcomes for the MHS community.

The DHA supports national security and ensures our nation’s military teams are ready to deploy. Seeking to leverage innovation and best practices from the commercial sector, the DHA conducted a thorough evaluation of the Amwell solution.

“We are delighted that the demonstrated scalability, flexibility, and comprehensiveness of the Amwell Converge platform, as evaluated by DHA, uniquely qualifies Amwell to support the DHA’s Digital First strategies and readiness mission. We are dedicated to supporting this program with the best that Amwell offers for many years to come,” said Dr. Schoenberg.

“Digital First addresses DHA’s goal of better outcomes, new processes, innovation and increased standardization based on evidence,” said Jason McCarthy, Leidos senior vice president, Military and Veterans Health Solutions. “As part of our overall MHS GENESIS effort to enhance patient experience, we, along with Amwell, are looking forward to providing near real-time, self-service support and hybrid care options for our customer and those whom they serve.”

Digital First will support the entire MHS community of users, which includes 9.6 million active-duty service members, family members, retirees, and health professionals across the continuum of care. Through integrated platform solutions, Amwell and Leidos will help reduce burdens on care teams, improve the mental health and wellness of beneficiaries, help reduce healthcare costs and optimize the effective utilization of DHA's clinical resources across their global enterprise.

About Amwell

Amwell provides a leading hybrid care enablement platform in the United States and globally, connecting and enabling providers, insurers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that hybrid care delivery will transform healthcare. The company offers a single, comprehensive platform designed to support all digital health needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With nearly two decades of experience, Amwell powers the hybrid care of more than 55 health plans, which collectively represent more than 90 million covered lives, and many of the nation’s largest health systems, representing over 2,000 hospitals, have access to Amwell solutions. For more information, please visit https://business.amwell.com/.

©2023 American Well Corporation. All rights reserved. Amwell®, SilverCloud®, ConvergeTM, CarepointTM and the Amwell Logo are registered trademarks or trademarks of American Well Corporation.

This press release contains forward-looking statements about us and our industry that involve substantial risks and uncertainties and are based on our beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations, financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” or “would,” or the negative of these words or other similar terms or expressions.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements represent our beliefs and assumptions only as of the date of this release. These statements, and related risks, uncertainties, factors and assumptions, include, but are not limited to: weak growth and increased volatility in the telehealth market; inability to adapt to rapid technological changes; increased competition from existing and potential new participants in the healthcare industry; changes in healthcare laws, regulations or trends and our ability to operate in the heavily regulated healthcare industry; our ability to comply with federal and state privacy regulations; the significant liability that could result from a cybersecurity breach; and other factors described under ‘Risk Factors’ in our most recent form 10-K filed with the SEC. These risks are not exhaustive. Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Further information on factors that could cause actual results to differ materially from the results anticipated by our forward-looking statements is included in the reports we have filed or will file with the Securities and Exchange Commission. These filings, when available, are available on the investor relations section of our website at investors.amwell.com and on the SEC’s website at www.sec.gov.